Gilead Sciences (GILD) : F&v Capital Management reduced its stake in Gilead Sciences by 1.15% during the most recent quarter end. The investment management company now holds a total of 61,230 shares of Gilead Sciences which is valued at $6,018,297 after selling 710 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Apr 13, 2016.Gilead Sciences makes up approximately 4.67% of F&v Capital Management’s portfolio.
Gilead Sciences opened for trading at $98.17 and hit $99.73 on the upside on Monday, eventually ending the session at $99.2, with a gain of 0.93% or 0.91 points. The heightened volatility saw the trading volume jump to 80,67,829 shares. Company has a market cap of $135,591 M.
Other Hedge Funds, Including , Somerset Trust Co boosted its stake in GILD in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 15,604 shares of Gilead Sciences which is valued at $1,533,717. Gilead Sciences makes up approx 1.01% of Somerset Trust Co’s portfolio.Searle boosted its stake in GILD in the latest quarter, The investment management firm added 220 additional shares and now holds a total of 14,570 shares of Gilead Sciences which is valued at $1,432,085. Gilead Sciences makes up approx 1.31% of Searle’s portfolio. Denali Advisors added GILD to its portfolio by purchasing 20,900 company shares during the most recent quarter which is valued at $2,054,261. Gilead Sciences makes up approx 0.46% of Denali Advisors’s portfolio.Kistler-tiffany Companies boosted its stake in GILD in the latest quarter, The investment management firm added 847 additional shares and now holds a total of 3,567 shares of Gilead Sciences which is valued at $341,826. Gilead Sciences makes up approx 0.19% of Kistler-tiffany Companies’s portfolio.New England Research Management reduced its stake in GILD by selling 6,390 shares or 67.41% in the most recent quarter. The Hedge Fund company now holds 3,090 shares of GILD which is valued at $296,115. Gilead Sciences makes up approx 0.25% of New England Research Management’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.